Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Truvada switch study

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A study in treatment-experienced HIV patients suggests patients switching from GlaxoSmithKline's Combivir (lamivudine/zidovudine) to Gilead's Truvada (emtricitabine/tenofovir) achieve significantly more viral suppression, Gilead reports Nov. 17. In the Phase IV COMET (Combination of Efavirenz and Truvada) study, presented at the European AIDS Conference Nov. 17 in Dublin, 76% of switched patients had viral load below 50 copies/mL compared to 59% at baseline (p<0.001); efavirenz (Bristol-Myers Squibb's Sustiva) was the background therapy in the study. Gilead has been highlighting Truvada's building sales momentum. Combivir continued to be the market leading nucleoside reverse transcriptase inhibitor in the third quarter, but Truvada sales were up 32%, putting it at the number three slot for the NRTI class (Pharmaceutical Approvals Monthly November 2005, p. 5)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS003140

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel